The investigation, spanning different categories of TKIs deployed in NSCLC-targeted therapies, revealed that EGFR-TKIs escalated the odds of QT interval prolongation relative to the complete database (ROR = 1.39, 99% CI: 1.08–1.80, IC025 = 0.18). Here, EGFR is linked to non-small cell lung carcinoma.